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The aim of the study was to investigate cancer stem signaling during the repopulation response of a head and neck squamous cell
cancer (HNSCC) xenograft after radiation treatment. Xenografts were generated from low passage HNSCC cells and were treated
with either sham radiation or 15Gy in one fraction. At different time points, days 0, 3, and 10 for controls and days 4, 7, 12, and
21, after irradiation, 3 tumors per group were harvested for global gene expression, pathway analysis, and immunohistochemical
evaluation. 316 genes were identified that were associated with a series of stem cell-related genes and were differentially expressed
(𝑝 ≤ 0.01 and 1.5-fold) at a minimum of one time point in UT-SCC-14 xenografts after radiation. The largest network of genes
that showed significant changes after irradiation was associated with CD44, NOTCH1, and MET. c-MET and ALDH1A3 staining
correlated with the changes in gene expression. A clear pattern emerged that was consistent with the growth inhibition data in that
genes associated with stem cell pathways were most active at day 7 and day 12 after irradiation. TheMET/CD44 axis seemed to be
an important component of the repopulation response.
1. Introduction
Head and neck squamous cell cancers (HNSCCs) are a
heterogeneous group of malignancies that originate in the
mucosal lining of the upper aerodigestive tract. Despite
advances in therapy, survival rates have remained static for
many years [1].
The heterogeneity of HNSCC, as evidenced by histo-
logical, phenotypical, and karyotypical analyses [2, 3], has
been mainly ascribed to the process of clonal expansion [4].
However, there is an increasing awareness that not all hetero-
geneity among cancer cells is the result of genetic variability
and that, within a single tumor clone, cells have significantly
different abilities to proliferate and formnew tumors.This has
led to the hypothesis that most cells in a cancer have a limited
ability to divide and only a small subset of phenotypically
distinct cells, the cancer stem cells (CSCs), have the capacity
to self-renew and form new tumors [5]. The presence of cells
with “stem-like” properties has been observed in HNSCC
using a variety of different approaches [6–11].
For advanced inoperable HNSCC, treated with radio-
therapy or chemoradiation, locoregional progression is the
principal cause of treatment failure and cancer-related death.
If tumor repopulation after therapy is a property of CSCs
then the response of this population to radiation will be a
critical constraint for curability. Several studies have provided
evidence that CSCs are more resistant to radiation than their
non-CSCs counterparts in a variety of cancers [12–15] and an
association with chemoresistance has been reported in many
studies including HNSCC [16].
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In this study, we developed a model of local failure and
repopulation in a HNSCC xenograft using a subcurative dose
of radiation and studied the changes in protein expression
of known stem cell-related genes as well as stem cell-related
signaling pathways using global gene expression at key time
points during the tumor response.
2. Materials and Methods
2.1. Cell Line, Xenografts, and Irradiation. The UT-SCC-14
cell line was obtained from Dr. R. Gre´nman, University of
Turku, Finland, and was selected from a large panel of cell
lines derived from primary and recurrent tumors from the
head and neck region. The cell line has been maintained
at low passage number such that it maintains phenotypic
and morphological characteristics similar to the primary
tumor which was a T3N1M0, moderately differentiated,
HPV negative squamous cell carcinoma of the oral tongue.
The experimental protocol was approved by the William
Beaumont Hospital Animal Care Committee. Four- to 6-
week-old female nude NIH III mice were used in these
studies. Mice were caged in sterile housing in groups of five
and were fed a diet of animal chow and water ad libitum.
Xenografts were established by harvesting UT-SCC-14 cells
in mid-log phase growth and injecting them subcutaneously
into the flank of themice, at a concentration of 2× 106 cells per
100 𝜇L of Matrigel (BD, Franklin Lakes, NJ). Tumor volume
was measured by digital calipers and calculated using the
standard formula (𝜋𝑎𝑏2)/6, where 𝑎 is the largest and 𝑏 is the
smallest diameter. When the tumor volume reached a value
of 300–400mm3, animals were randomly assigned to the
experiment groups. Tumors were measured three times each
week. The endpoint of the experiment was when the tumors
grew to a volume of 3,000mm3. Animals were irradiatedwith
a Faxitron Cabinet X-Ray System, Model 43855F (Faxitron
X-Ray, Wheeling, IL), at a dose rate of 0.69Gy/min, tube
voltage of 160KVp, and current of 4mA. Animals were
immobilized (without anesthetic) in a custom-designed jig
that only exposed the hind flank to the radiation beam.
2.2. Experimental Design. Nine xenografts were randomized
to receive sham treatment (control group) and twelve were
randomized to receive 15Gy (RT group). Groups of 3 mice
from each treatment cohort were sacrificed at different time
points after treatment. The control time points were selected
during exponential growth of the unirradiated tumor and
were not linked to the irradiated time points which were
based on the regrowth characteristics of the tumors to
yield observations during growth inhibition, transition to
regrowth. At each time point the tumor was rapidly excised,
bisected, and half snap-frozen and stored at −80∘C whilst the
other half was fixed in zinc formalin. For the control group,
tumors were harvested at days 0, 3, and 10 after reaching the
starting volume of 400–500mm3. For the RT group, tumors
were harvested at days 4, 7, 12, and 21 after treatment.
2.3. Isolation of RNA and Gene Expression. Laser capture
microdissection was used to isolate cells from the peripheral
regions of the tumor based on our previous observation
of central necrosis after radiation treatment [17]. Frozen
tissue samples were embedded in OCT (Tissue-Tek; Sakura
Finetek, USA) and 8 𝜇m sections were cut and mounted onto
PEN (polyethylene naphthalate) membrane glass slides (two
sections per slide). Regions of periphery were identified on
corresponding H&E slides of the tissue sections. The stained
slides were microdissected within 2 hours of sectioning using
an ArcturusXT Microdissection System (Molecular Devices)
onto CapSure Macro LCM Caps (Molecular Devices).
RNA isolation was carried out using RNeasy Plus Micro
Kit (Qiagen, Valencia, CA). RNA concentration was deter-
mined on a ND-8000 spectrophotometer (NanoDrop Tech-
nologies, Inc., Wilmington, DE) and quality assessed on a
Model 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA). High-quality RNA (i.e., RIN > 9.5) was used for the
experiments. DifferentialmRNA expression analysis between
cell populations was performed according to the GeneChip
Whole Transcript (WT) SenseTarget LabelingAssay Protocol
(Affymetrix Inc., Santa Clara, CA) using 100 ng of RNA from
each specimen. The fragments were hybridized overnight
with the Human Exon 1.0 ST Array and then scanned with
a GeneChip Scanner 3000. The GEO accession number is
GSE61573.
2.4. Data Analysis. The .CEL files containing the raw inten-
sity data from theAffymetrixGeneChip arrayswere imported
into Partek Genomics Suite (version 6.6 beta, build 6.11.1115)
and normalized using the robust multichip average with
a guanine-cytosine content background correction, quan-
tile normalization, log
2
-transformation, and median polish
probeset summarization. Exons were then summarized to
genes using the average of the probesets. Differentially
expressed genes were identified using 1-way ANOVA com-
paring the samples from a given irradiated time point to the
controls.
Gene set enrichment analysis (GSEA) and pathway analy-
ses were performed using Pathway Studio 10.3 (Elsevier, New
York, NY, USA). GSEA identifies highly regulated categories
by considering all genes without any prefiltering based upon
𝑝 value or fold change [18]. The expression microarray
data was also analyzed using Pathway Studio’s Sub-Network
Enrichment Analysis (SNEA) tool [19, 20]. Pathway Studio
utilizesMedScan, the literaturemining program that searches
publicly available literature such as PubMed for relationships
between entities [21]. A subnetwork consists of a single
seed (i.e., disease or cell process) and genes associated with
this seed by regulation of/by the seed [22]. The expression
microarray dataset is interrogated with no prior significance
filtering, and enrichment of the subnetwork is determined by
both the level of regulation in the network and the size of the
network. The visualized subnetwork was limited to include
only those genes that met 𝑝 ≤ 0.01 and 1.5-fold change.
2.5. Immunohistochemistry and Image Analysis. 4 𝜇m sec-
tions were cut, deparaffinized, and hydrated by passing
through xylene followed by graded alcohol to distilled
water. Antigen retrieval was achieved using antigen unmask-
ing solution (pH 9.0) (Vector Labs, Burlingame, CA).
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Endogenous peroxide was blocked with Envision Flex per-
oxidase blocking solution (Dako, Carpinteria, CA) and the
nonspecific staining blocked with CAS universal blocking
solution (Life Technologies, Grand Island, NJ). Rabbit poly-
clonal antibodies for CD44 and ALDH1A3 were obtained
from Abcam and used at a dilution of 1 : 50; c-MET clone
8F11 (Vector Laboratories Inc., Burlingame, California, USA)
was diluted 1 : 100 and incubated at 42∘C for 2 hours; (Abcam,
Cambridge, MA) CD44 and ALDH1A3 were diluted 1 : 50
and 1 : 100, respectively, in antibody diluent containing PBS
(pH 7.4), BSA, and 0.05% sodium azide and incubated for
60 minutes. After washing, the sections were incubated
for 20 minutes using a dual rabbit/mouse polymer link
detection kit (Dako) and visualized using diaminobenzidine
and counterstained with hematoxylin. The sections were
then dehydrated with a gradient of ethanol to xylene and
coverslipped.
Images were captured at 10x magnification on a Nikon
90i microscope (Nikon,Melville, NY) equipped with a Nikon
DS-Fi1 digital camera and Nikon Elements software. Ten
imageswere captured from the peripheral areas of each tumor
sample. The percent area of the image that stained positively
for each protein was analyzed using ImageJ software (NIH).
Images were split using the RGB function, an autothreshold
was set on the blue image, and the area showing positive DAB
staining was calculated using the measure function.
2.6. Statistical Analysis. Statistical analysis was carried out
using Student’s 𝑡-test. Data are presented as mean ± SE.
A probability level of a 𝑝 value of <0.05 was considered
significant.
3. Results
3.1. Tumor Characteristics, Growth Rate, and Response to
Radiation. Figure 1 shows the time course of the radiation
response in the UT-SCC-14 xenografts. The untreated UT-
SCC-14 xenografts had a volume doubling time of 4.8 ±
0.7 days whilst the irradiated tumors showed a period of
profound growth arrest until day 12 after which they transi-
tioned into repopulation. In a different aspect of this present
study, we showed that early radiation necrosis (days 4–12) was
characterized by central coagulative necrosis with pyknotic
nuclei whilst late radiation necrosis (day 12 onwards) was
characterized additionally by extensive necrosis with frag-
mentation and dystrophic calcifications [17]. The histolog-
ical studies demonstrated that repopulation of the tumor
occurred from the peripheral region, and this was the reason
why immunohistochemical and gene expression analysis was
restricted to only this region in the control and treated
animals by the use of laser capture microdissection.
3.2. Immunohistochemical Staining of Stem Cell-Associated
Proteins. Figure 2(a) shows the immunohistochemical stain-
ing pattern and changes after irradiation of 3 of the genes with
known association to stem cells in HNSCC; in Figure 2(b),
the quantitative analysis of these genes is presented. CD44
was mainly associated with the cell surface and tended to
stain cells in the outer layers of the tumor islands formed
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Figure 1: The tumor growth response of UT-SCC-14 xenografts to
a dose of 15Gy. Flank tumors were either irradiated with 15Gy (󳵻)
or sham-irradiated (O) and their growth was monitored over time
with calipers.
by the UT-SCC-14 cells; no staining was observed in the
stroma. Following radiation, there was not a great change
in the intensity of staining but the number of positive cells
fell steadily at day 4 (𝑝 = 0.0201) and day 7 (𝑝 =
0.0123) and to a nadir at day 12 (𝑝 = 0.0014) after which
expression levels recovered. The staining pattern became
more predominantly associated with the outermost cell layers
of the tumor islands. In control tumors there was a reduction
inCD44 expression as tumor volume increased. Interestingly,
CD44 expression decreased in control tumors as a function
of time. Histologically, this was associated with a tendency
for the larger tumors to show differentiation and increased
keratinization.
ALDH1A3 staining was cytoplasmic and showed a diffuse
pattern throughout the tumors where complete tumor islands
were often positive with little evidence of any preferential
peripheral staining within those islands. After irradiation
ALDH1A3 increased to a maximum on day 7 (𝑝 = 0.047)
and remained elevated for the period of observation. In some
areas cells became more intensely stained with ALDH1A3
after irradiation.
Intrinsic levels of c-MET were relatively low in UT-
SCC-14 xenografts and showed a staining pattern which was
similar to ALD1A3 being diffuse and cytoplasmic. The levels
of c-MET increased at day 7 (𝑝 = 0.0357) and reached a
maximum at day 12 (𝑝 = 0.005) after which they declined
rapidly to control levels.
3.3. Global Gene Expression Changes Associated with Stem
Cell-Related Signaling. In Table 1, Pathway Studio software
was used to identify genes associated with a series of stem
cell-related genes CD44, ALDH, MET, NOTCH1, BMI1,
OCT3/4, NANOG, SOX2, and CD133, which were differen-
tially expressed (𝑝 ≤ 0.01 and 1.5-fold) at a minimum
of one time point in UT-SCC-14 xenografts after radiation.
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Figure 2: Immunohistochemical staining for CD44, ALDH1A3, and c-MET (a) and image analysis quantification of protein expression (b)
after radiation (RT) treatment. CD44 was mainly associated with the cell surface and tended to stain cells in the outer layers of the tumor
islands; its expression decreased after radiation but recovered between days 12 and 21. ALDH1A3 staining was cytoplasmic and showed a
diffuse pattern throughout the tumors. After irradiation ALDH1A3 increased to a maximum on day 7 and remained elevated for the period
of observation. In some areas cells became more intensely stained with ALDH1A3 after irradiation. c-MET showed a staining pattern which
was similar to ALDH1A3 being diffuse and cytoplasmic.The levels of c-MET increased at day 4 and reached a maximum at day 12 after which
they declined rapidly to control levels (×20).
The associated genes could be of any category including
ligand, transcription factor, positive or negative regulator,
or receptor. Pathway Studio identified 316 genes that met
these criteria for the 9 stem cell-related genes, many of which
were shared between the target genes. The largest network
of genes that showed significant changes after irradiation
was associated with CD44, NOTCH1, andMET. The smallest
network of genes was associated with ALDH. There was a
clear pattern that emerged in which genes associated with
stem cell pathways were most active at day 7 and day 12 after
irradiation. At day 7, the tumors are still in a state of profound
growth inhibitionwhilst at day 12 the transition into regrowth
is becoming apparent (Figure 1). At days 4, 7, and 12, there
was a higher proportion of genes that were upregulated in
the stem cell-associated pathways but, interestingly, at day
21 (during active regrowth) more downregulated genes were
represented.
3.4. Specific Gene Expression Changes Associated with Stem
Cell Signaling. Three genes, CTNNB1,MMP9, and NOTCH1,
were identified in the pathways of all of the nine stem cell-
associated genes. However, CTNNB1 was only upregulated
at day 4; MMP9 was upregulated at days 12 and 21, whilst
NOTCH1 was downregulated at days 12 and 21. Three genes,
IL6, IL8, and SMAD2, were represented in 8 of the 9 signaling
pathways. SMAD2 was only upregulated at day 7 whilst both
IL6 and IL8 were upregulated at day 12. Seven genes were
present in 7 of the 9 pathways and included ICAM1, LIF,
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Table 1: Genes differentially expressed (𝑝 ≤ 0.01 and 1.5-fold)
at a minimum of one time point in UT-SCC-14 xenografts after
radiation.
Gene 𝑛 Day 4 Day 7 Day 12 Day 21
↑ ↓ ↑ ↓ ↑ ↓ ↑ ↑
CD44 62 5 3 20 12 28 11 3 4
ALDH 9 2 0 2 4 3 1 1 1
MET 48 7 1 16 8 25 9 4 5
OCT3/4 37 6 1 10 5 18 4 4 4
BMI1 16 1 0 2 7 6 1 0 1
NOTCH1 66 7 4 19 14 29 11 1 4
NANOG 29 5 2 7 4 15 4 4 3
SOX2 29 3 1 8 5 12 3 1 2
CD133 20 2 1 3 4 9 3 0 3
Total 316 38 13 87 63 145 47 18 27
Using Partek Genomics software and Pathway Studio, genes that were
differentially expressed at a minimum of one time point after radiation with
a 𝑝 value ≤ 0.01 and fold change (negative or positive) of 1.5 or greater were
identified for each of the CSC-associated genes. For each gene, 𝑛 represents
the total number of identified genes in each pathway whilst the ↑ and ↓
arrows for each day after radiation represent the number of genes whichwere
upregulated or downregulated, respectively.
MAPK8, MET, SPP1, TGFA, and TGFBR2. MET and TGFA
were upregulated at key days 7 and 12. LIF1 and SPP1 were
upregulated at day 12 whilst MAPK8 was upregulated at day
7 only.
3.5. Specific Gene Expression Changes Associated with CD44.
Supplemental Table 1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2016/1894782 shows genes
significantly altered at one time point or more known to
be associated with CD44 signaling. It is clear that the
greatest activity centers on days 7 and 12. On day 7 the
genes showing the greatest fold change were as follows:
TIMP3 (+2.44), TIMP2 (+2.39), IGHMBP2 (+2.36), MMP3,
KHDRB53, TGFA, and WIPF1 all showed between 1.90-
and 1.99-fold increases whilst PTGES, PLAUR, CTSB, MET,
and VANGL1 all showed greater than 1.75-fold increases.
The top downregulated genes were IGFBP5 (−3.40), PTTG1
(−3.07), EGR1 (−2.55), and FASN (−2.54). On day 12 more
genes showed significant alterations and higher levels of
fold change. IL8 (+6.00), HAS2 (+5.35), ICAM1 (+3.51),
PLAUR (+3.32), LIF (+3.13), and LYN (+3.07) were the
most significantly upregulated genes but TIMP2, MMP9,
HBEGF, CXCL16, SLC7A11, MME, EPCAM, CTSS, PLAU,
and TGFBR2 all showed greater than 2-fold upregulation.
Of the downregulated genes IGFBP5, BCAM, and NOTCH1
showed the greatest downregulation. InterestinglyHRASwas
downregulated on days 7, 12, and 21.
3.6. Specific Gene Expression Changes Associated with MET.
Supplemental Table 2 shows thatMET shares many common
genes with CD44 and shows a similar pattern of the most
active gene expression changes taking place on days 7 and
12. Some of the key genes upregulated on day 7 were
WNT7A (+2.46), TIMP3 (+2.44), TIMP2 (+2.39), MMP3
(+1.99), TGFA (+1.91), and PLAUR (+1.84). MET itself was
upregulated 1.76-fold and was also upregulated at day 12
1.86-fold. Several genes were highly upregulated in the c-
MET pathway at day 12 including LCN2 (+10.0), IL8 (+6.0),
ICAM1 (+3.51), PLAUR (+3.32), LIF (+3.13), LYN (+3.07),
TIMP2 (+2.92),MMP9 (+2.82),HBEGF (+2.76), andWNT7A
(+2.25). Some of the most noticeable downregulated genes
were HRAS, FASN, EGR1, FGFR3, and NOTCH1.
3.7. Specific Gene Expression Changes Associated with
NOTCH1. Supplemental Table 3 shows that NOTCH1 also
shares many common genes with CD44 and MET and
reflects the changes in WNT7A, TIMP3, TIMP2, MMP3,
TGFA, PLAUR, and MET at day 7. Other genes upregulated
in this pathway at day 7 included FHL1 (+2.45), NFATC2
(+2.04), and ENO2 (+2.03). Similarly, at day 12 many mutual
genes were upregulated including IL8, ICAM1, PLAUR,
LIF, TIMP2, MMP9, HBEGF, and WNT7A; other notable
upregulated genes included IL1RL1, FHL1, IL6ST, TRIB3,
PMAIP1, RIPK2, PLAU, TGFBR2, TGFA, BIRC3, and BMI1.
IGFBP5, NOTCH1, JAG2, HRAS, and STAT6 were notable
genes downregulated at day 12.
3.8. Specific Gene Expression Changes Associated with Other
Stem Cell-Related Genes including ALDH, BMI1, CD133,
NANOG, POU5F1, and SOX2. The ALDH, BMI1, CD133,
NANOG, POU5F1, and SOX2 pathways had fewer members
whichwere significantly altered after radiation (Supplemental
Tables 4–9). ALDH1A3 was the key gene in the ALDH
pathway that was upregulated at day 7 (+2.18), day 12 (+4.18),
and day 21 (+2.75). The BMI1 pathway showed nothing
remarkable outside of genes altered inmany of the other path-
ways.Therewas a similar conclusionwith theCD133 pathway.
The NANOG and POU5F1 (OCT 3/4) pathways shared some
similar upregulated genes which were not associated with the
other major signaling pathways. These included TOR1AIP2
which was upregulated at day 4 (+3.5), day 7 (+4.27), and
day 12 (+3.75) and PMP22 which was upregulated at day 7
(+3.32), day 12 (+3.02), and day 21 (+1.95). SOX2 signalingwas
relatively unremarkable withmost genes being represented in
the other major pathways.
3.9. Common Cell Processes Associated with Stem Cell Signal-
ing after Radiation Treatment. Figure 3 shows cell processes
that were linked with all nine stem cell-associated genes.
Apoptosis and differentiation were almost universally nega-
tively regulated by the genes whilst cell growth, cell prolif-
eration, cell migration, and epithelial-to-mesenchymal tran-
sition were positively regulated by the stem cell-associated
genes.
3.10. Epithelial-to-Mesenchymal Transition. Epithelial-to-
mesenchymal transition (EMT) appears as a common cell
process in Figure 3, and it functions to diversify cell types
during embryogenesis and also allows epithelial cells to
acquire a migratory, mesenchymal-like phenotype during
wound healing. Inducing EMT in HNSCC cells correlates
with the emergence of CSCs and vice versa. In Supplemental
Table 10, we have listed the genes showing 𝑝 ≤ 0.01 and at




Apoptosis Cell proliferationCell growth Epithelial-to-mesenchymal transition Cell differentiation Cell migration
Figure 3: Cellular processes common to all nine cancer stem cell- (CSC-) associated genes. Pathway Studio was used to identify known
relationships and cellular processes that are common between the CSC-associated genes. The⨁ symbol on the arrow represents positive
regulation of the process whilst a – through the arrow represents negative regulation.
least a 1.5-fold change after irradiation. There is a similar
pattern to the stem cell-associated genes where significant
changes increase from day 4 through day 7, peak at day 12,
and decline by day 21. Many of the genes are shared among
the stem cell-associated gene pathways. In Figure 4, we have
linked the pathways of the stem cell-associated genes with
EMT presenting common genes found in at least 5 of the
9 CSC markers and EMT with a differential expression of
𝑝 ≤ 0.01 and at least a 1.5-fold change. CTNNB1 and MMP9
were the only genes linked to all the subnetworks whilst IL8,
IL6, and SMAD2 were found in 9 of the ten subnetworks and
ICAM1, SPP1, TGFA, LIF, TGFBR2, andMAPK3 were found
in 8 subnetworks.
4. Discussion
It is generally accepted that CSC populations with self-
renewal and differentiation capacities exist within HNSCC
[16, 23]. A better understanding of the mechanisms that
govern the dynamics of HNSCC CSCs is needed to unravel
their importance and role in treatment resistance and disease
progression. In this study, we developed a model which
interrogated the molecular changes associated with known
stem cell linked genes during the repopulation/regrowth of
a HNSCC xenograft after a subcurative radiation treatment.
The underlying rationale for this approach was that if the
CSCs were important in treatment resistance, they would
dominate the repopulation response as a single dose of 15Gy
would kill approximately 90% of the cells in the tumor.
Many of the genes including CD44 [24], BMI1 [25], c-
MET [26], NOTCH1 [27], ALDH1 [28], and SOX2 [29] have
been associated with poor prognosis in HNSCC. However,
the genes were specifically chosen in this study because
they have all been associated with CSCs in HNSCC and
other cancers. CD44 is a multifunctional transmembrane
glycoprotein that is a receptor hyaluronic acid but can also
interact with several additionalmolecules such as fibronectin,
fibrinogen, laminin, galectin-8, collagen, chondroitin sulfate,
and osteopontin. It has been proposed that HA binding to
CD44 promotes its association with EGFR as well as EGFR
phosphorylation. CD44 is the most commonly used cell-
surface marker for CSCs across multiple tumor types and has
been consistently acknowledged as CSC marker in HNSCC
[30, 31]. Prince and colleagues were the first to show CD44+
cells were highly tumorigenic and successfully propagated
in serial transplantation studies [10]. CD44 expression has
been associated with poor prognosis in HNSCC [24]. The
aldehyde dehydrogenase family of enzymes participates in
retinoic acid biosynthesis and is an integral component of
squamous epithelia differentiation. Cells which express high
levels of ALDH1, extracted from primary HNSCC, were
shown to be more tumorigenic in establishing xenografts
than cells with low expression [6] and other studies have
shown that ALDH1 overexpression correlates with poor
prognosis [32]. The combination of CD44+ and ALDHhigh
expression further identified primary HNSCC cells that
showed enhanced xenotransplantation efficiency [33]. c-
MET is a receptor tyrosine kinase that has been implicated
in the progression of HNSCC [34] and associated with
worse response to treatment and prognosis [26]. It has also
been implicated in CSCs as a subset of c-MET+ cells were
shown to have enhanced tumorigenicitywhichwasmore pro-
nounced when cells which were positive for both c-MET and
CD44 were transplanted [35]. NOTCH1 signaling ordinarily
drives keratinocyte differentiation in squamous epithelia [36]
but takes on stemness-promoting activity upon malignant
transformation [37]. The expression of NOTCH1 and 𝛽-
catenin has been reported to be increased in CD44+ HNSCC
cells [38]. CD133 (also known as AC133 or prominin-1) is
a cell-surface glycoprotein comprising five transmembrane
domains and two large glycosylated extracellular loops and
has commonly been associated with subpopulations of cells






































































































































































































































































































































Figure 4: Changes in genes associated with epithelial-to-mesenchymal transition after radiation. Using Pathway Studio, genes known to be
associated with epithelial-to-mesenchymal transition and differentially expressed at a minimum of one time point after radiation with a 𝑝
value ≤ 0.01 and fold change (negative or positive) of 1.5 or greater were identified. Red represents genes upregulated after irradiation whilst
blue represents downregulated genes.
with highly tumorigenic capacity in several cancers including
HNSCC [39]. BMI1 is a member of the Polycomb family of
transcription repressors. Emerging studies show that BMI1
has an important function as a biomarker of CSCs and is
associated with self-renewal characteristics, tumor initiation,
progression, invasion, metastasis, tumor recurrence, and
resistance to chemotherapy and radiotherapy [40]. NANOG,
POU5F1 (Oct-3/Oct-4), and SOX2 are transcription factors
that are important in the maintenance of pluripotency and
self-renewal in embryonic stem cells [41]. All these genes have
been implicated in cancer stem cell traits in HNSCC [42].
There was a clear sequence of events that occurred in
the signaling pathways for each of the stem cell-associated
genes in that the number of significantly altered components
increased from day 4 after irradiation to day 7, peaked
at day 12, and returned to near control levels by day 21.
This sequence could be interpreted to represent the initial
killing of radiation-sensitive cells, the recovery dominated
8 Stem Cells International
by changes in the surviving radiation-resistant stem cell
population, and then the return to normal activity driven
by differentiation of stem cells into the original tumor
phenotype. However, this is speculation as the changes in
subpopulations of cells within the tumor cannot be verified
by the current experimental design. The only principal gene
thatwas upregulated at days 7 and 12wasMET (1.76- and 1.86-
fold, resp.), whilst the ALDH1 family member ALDH1A3 was
upregulated at day 7 (+2.18), day 12 (+4.18), andday 21 (+2.75).
Both these genes also showed increased protein expression
as evidenced by immunohistochemistry (Figure 2). BMI1was
modestly upregulated at day 12 (+1.53) whilst NOTCH1 was
downregulated at day 12 (−2.11).The likely sequence of events
following a single dose of 15Gy would be initial killing of
radiosensitive cells followed by a prolonged cell cycle delay
with further rounds of cell death as cells attempt mitosis
in the presence of unrepaired DNA damage. Accelerated
repopulation during radiation has been described for many
years [43] but the underlying stimulus for repopulation has
not been well studied at the mechanistic level [44, 45].This is
the first study to specifically look at stem cell signaling during
the process of repopulation in an in vivo tumor model.
Each stem cell-associated gene was characterized by its
own network of ligands, transcription factors, positive or
negative regulators, or receptors which were significantly
altered on different days after radiation treatment. However,
there were genes that were common to many of the stem
cell-associated genes including CTNNB1, MMP9, IL8, IL6,
SMAD2, ICAM1, SPP1, TGFA, LIF, TGFBR2, and MAPK3.
The key time period is likely to be the events and signaling
that takes place between day 7 and day 12. At this time, the
tumor (and stromal) cells will be recovering from the single
large radiation dose and the pathways that are activating
the repopulation response will become dominant. This time
period witnessed the most activity in terms of significantly
altered genes linked with stem cell-associated genes as well as
with the epithelial-to-mesenchymal transition. Interestingly,
the NOTCH pathway did not seem to be activated following
radiation; the gene NOTCH1 was downregulated at day 12,
one of its canonical transmembrane ligands JAG2 was down-
regulated at days 7 and 12, and its target gene HEY1 was also
downregulated at day 12. The NOTCH pathway is one of the
most intensively studied candidate genes involved in CSCs,
andNOTCH signaling has been reported to promote the self-
renewal of CSC in several malignancies and to participate in
tumor-stroma and tumor-endothelium interactions in CSC
niches in primary and metastatic tumors [46]. Another gene
which has been reported to be important in CSCs in head
and neck cancer [40], BMI1, also did not show any significant
changes during the repopulation response.
One of the most intriguing findings was centered on
ALDH1.This gene has been consistently associatedwith CSCs
in head and neck cancer [47, 48]. In our study ALDH1A3
was significantly upregulated at days 7, 12, and 21 as were the
protein levels by immunohistochemistry (Figure 2), yet there
were very few other family members that showed significant
changes (Supplemental Table 4). ALDH is an intracellular
enzyme that is normally active in the liver. Its primary func-
tions are retinol conversion to retinoic acid and the oxidation
of toxic aldehyde metabolites, such as those formed during
the alcohol metabolism and certain chemotherapeutic drugs.
It would seem to be a very significant biomarker for the
identification of stem cells but offers little opportunities to
design drugs to target its associated pathways. However,
adoptive therapy with ALDH1A1-specific CD8(+) T cells is a
promising approach to target CSCs based on this biomarker
[49].
The MET/CD44 axis seems to be an important compo-
nent of the CSC response in this HNSCC tumor model.
Like ALDH1, MET gene expression and protein expression
(Figure 2) were significantly altered at the key time points
after irradiation. However, CD44 gene expression was not
changed, and CD44 protein initially decreased following
radiation before showing a recovery at day 12. c-MET signal-
ing plays a critical role in tumor progression, invasion, and
metastasis, and we have recently shown it to be associated
with poor prognosis in locally advanced HNSCC patients
treated with chemoradiation [26]. Sun and Wang showed
that c-MET(+) HNSCC cells increased expression of self-
renewal pathways, were spared by cisplatin treatment, and
were responsible for mediating metastasis [35]. When CD44
expression was taken into account in addition to c-MET,
the dual biomarker expressing population showed enhanced
tumorigenicity [35]. A recent study showed that hepatocyte
growth factor (the only known ligand for c-MET) stimula-
tion increased the self-renewal and expression of stemness
markers, such as Oct4, Sox2, Nanog, and CD44, in HNSCC
stem-like cells [50]. In addition, knockdown of c-MET atten-
uated CSC traits, augmented cisplatin chemosensitivity, and
inhibited xenotransplantation efficiency. Inhibiting c-MET
using a kinase inhibitor, SU11274, inhibited sphere formation
and suppressed the transcriptional levels of Oct4 and Sox2 of
HNSCC stem-like cells [50]. It is difficult to decipher which
are the key genes involved in theMET/CD44 axis, but IL-8 has
been shown to act as an autocrine growth factor in HNSCC,
melanoma, and lung carcinoma and addition of recombinant
IL-8 can promote directly the proliferation of HNSCC cell
lines [51].
EMT is also linked with the acquisition of stem cell-
like characteristics. The concept of EMT inducing a CSC
phenotype provides a possible mechanistic basis for metas-
tasis, chemoresistance, tumor dormancy, and delayed recur-
rence. It is difficult to recognize the morphological cellular
changes associated with EMT after radiation due to the
cellular changes induced by the treatment which include
enlarged nuclei with degenerative atypia, smudged chro-
matin, pyknotic nuclei, and micro-/macrovesicular vacuola-
tion of cytoplasm [17]. However, the gene expression analysis
highlighted the importance of EMT-associated genes in the
repopulation response suggesting that this cellular process
is a key component of the tumor response to recovery from
cytotoxic damage.
In summary, stem cell-associated gene signaling is a key
component of the response of HNSCC to DNA damage and
may be driver of the repopulation response of the tumor.The
limitation of this study is that experiments were performed
on one tumor model and further work will be required using
different HNSCC tumor models to validate these findings. In
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addition, the model used a single dose of irradiation; further
work will be required using fractionation schedules with
different total doses to confirm these findings in a clinically
realistic schedule. With these limitations, this study indicates
that the MET/CD44 axis would seem to be an important
contributor to the recovery/regrowth response.
5. Conclusion
Although CSCs have been consistently identified in HNSCC
and shown to be capable of enhancing tumorigenicity and
resistance to chemotherapy, there has been no study that
attempts to decipher their importance in the repopula-
tion/regrowth response of HNSCC to radiation treatment. In
this study, we have demonstrated that several pathways asso-
ciated with known stem cell-associated genes show a similar
response after irradiation that is consistent with the transition
from damage recovery to regrowth of a HNSCC xenograft
in vivo. The study highlights the potential importance of the
MET/CD44 axis as well as the importance of epithelial-to-
mesenchymal regulators in the recovery process after DNA
damage caused by radiation.
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